It is important for regulatory clinical trials for ulcerative colitis to acknowledge that concomitant exposure to common medications does not affect UC treatment efficacy or safety. Concomitant use of ...
Immunomodulatory drug users were significantly less likely to discontinue pegloticase compared to non-users with no additional concerning lab or safety findings. Concomitant immunomodulatory drug use ...
Integrating electronic health records (EHRs) to facilitate cancer biomarker testing: Real-world implementation barriers and solutions. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
Bridging the Gap: Transforming Total Neoadjuvant Therapy: NEOTERIC Signals a Step Forward in the Treatment of Locally Advanced Rectal Cancer In solid tumor oncology, immunotherapy has demonstrated the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results